Atlas Trials

Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)

Clinical trial NCT02919371 · UNKNOWN

Trial details

NCT number
NCT02919371
Sponsor
King Faisal Specialist Hospital & Research Center
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Renal Cell Carcinoma
Start date
2014-12-01
Primary completion
2020-12-01
Enrollment
77

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.